BRD4 and prostate carcinoma: It could also efficiently induce ubiquitinproteasomal degradation of BRD4 in AR-positive prostate cancer cell lines, with sub-nanomolar half-maximal degradation concentrations (DC50) and maximum degradation (Dmax) > 99%.